Take off with LAVA Therapeutics NV (LVTX): Get ready for trading

With 1.8 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.44 million shares. The 52-week range on LVTX shows that it touched its highest point at $6.47 and its lowest point at $0.85 during that stretch. It currently has a 1-year price target of $2.33. Beta for the stock currently stands at 0.46.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LVTX was up-trending over the past week, with a rise of 45.16%, but this was up by 39.18% over a month. Three-month performance dropped to -8.78% while six-month performance fell -28.57%. The stock lost -34.78% in the past year, while it has gained 41.96% so far this year. A look at the trailing 12-month EPS for LVTX yields -1.03 with Next year EPS estimates of -1.35. For the next quarter, that number is -0.29. This implies an EPS growth rate of 27.07% for this year and -18.12% for next year. EPS is expected to grow by 25.72% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 86.55%.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for LVTX since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.91981 being high and -$1.47756 being low. For LVTX, this leads to a yearly average estimate of -$1.10573. Based on analyst estimates, the high estimate for the next quarter is -$0.34 and the low estimate is -$0.35. The average estimate for the next quarter is thus -$0.34.